SCICLONE PHARMACEUTICALS, INC. EXECUTIVE SEVERANCE AGREEMENTExecutive Severance Agreement • March 31st, 2011 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations • California
This Executive Severance Agreement (the “Agreement”) is effective as of May 4, 2010, by and between Gary Titus (the “Executive”) and SciClone Pharmaceuticals, Inc., a Delaware corporation (the “Company”).
AMENDMENT NO. 1 TO CHANGE IN CONTROL AGREEMENTChange in Control Agreement • March 31st, 2011 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment Number One effective as of July 9, 2010 (the “Amendment”) amends that certain Change of Control Agreement dated May 1, 2007 (the “Agreement”) by and between SciClone Pharmaceuticals, Inc. (the “Company”) and Israel Rios, M.D. (“Employee”). Capitalized terms not otherwise defined herein shall have the meaning ascribed them in the Agreement.
ASSIGNMENT AND PURCHASE OF INTELLECTUAL PROPERTY RIGHTS AGREEMENTAssignment and Purchase of Intellectual Property Rights • March 31st, 2011 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations • California
This Assignment and Purchase of Intellectual Property Rights Agreement (the “Agreement”) is made by and among Edward T. Wei, an individual whose address is 480 Grizzly Peak Blvd., Berkeley, CA 94708 (“Wei”), Cragmont Pharmaceuticals, LLC, a Delaware limited liability company, having a place of business at 480 Grizzly Peak Blvd., Berkeley, CA 94708 (“Cragmont”), certain Russian inventors (“Russian Inventors”) and Russian companies (“Russian Companies”) (collectively, the “Russian Assignors”) and all four (Wei; Cragmont; Russian Inventors; Russian Assignors) collectively the “Assignors” and SciClone Pharmaceuticals, Inc., a Delaware corporation, with offices located at 950 Tower Lane, Suite 900, Foster City, California 94404) and SciClone Pharmaceuticals International, Ltd., a Cayman corporation (collectively, the “Assignees”), as of December 28, 2010 (the “Effective Date”).
AMENDMENT NO. 2 TO CHANGE IN CONTROL AGREEMENTChange in Control Agreement • March 31st, 2011 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment Number Two effective as of May 4, 2010 (the “Amendment”) amends that certain Change of Control Agreement dated June 2, 2006, as amended on April 7, 2009 (the “Agreement”) by and between SciClone Pharmaceuticals, Inc. (the “Company”) and Dr. Friedhelm Blobel (“Employee”). Capitalized terms not otherwise defined herein shall have the meaning ascribed them in the Agreement.
AMENDMENT NO. 1 TO MANUFACTURING AND SUPPLY AGREEMENTManufacturing and Supply Agreement • March 31st, 2011 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO MANUFACTURING AND SUPPLY AGREEMENT (this “Amendment”) effective as of December 23, 2010 (the “Amendment Date”), is entered into between SciClone Pharmaceuticals International Ltd., with offices located at Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands (hereinafter, “Customer” or “SPIL”), and Lonza Sales Ltd., having an address at Muenchensteinerstrasse 38, CH-4002 Basel, Switzerland (hereinafter, “Manufacturer” or “Lonza”) (collectively, referred to as the “Parties” or individually, a “Party”).
AMENDMENT NO. 1 TO CHANGE IN CONTROL AGREEMENTChange in Control Agreement • March 31st, 2011 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment Number One effective as of July 9, 2010 (the “Amendment”) amends that certain Change of Control Agreement dated April 22, 2003 (the “Agreement”) by and between SciClone Pharmaceuticals, Inc. (the “Company”) and Hans P. Schmid (“Employee”). Capitalized terms not otherwise defined herein shall have the meaning ascribed them in the Agreement.
AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENTEmployment Agreement • March 31st, 2011 • Sciclone Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment Number Two effective as of May 4, 2010 (the “Amendment”), amends that certain Employment Agreement dated June 2, 2006, as amended on April 7, 2009 (the “Agreement”) by and between SciClone Pharmaceuticals, Inc. (the “Company”) and Dr. Friedhelm Blobel (“Employee”). Capitalized terms not otherwise defined herein shall have the meaning ascribed them in the Agreement.
